A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent

A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and optionally (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Traz...

A stable liquid pharmaceutical composition comprising an aqueous solution of a pharmaceutically acceptable salt of acid addition of trazodone characterized in that said pharmaceutical composition has a pH value between 5.0 and 6.0 and comprises at least two cosolvents selected from the group comprising glycols and polyglycols.

A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and optionally (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Traz...

A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent

PROBLEM TO BE SOLVED: To provide a once-daily formulation for trazodone or a derivative thereof.

PURPOSE: A sustained release formulation using a gastric retention drug delivery system is provided to enable drugs to stay in the gastrointestinal tract for a long time and release the drugs continuously by adding a first controlled-release base and a second controlled-release base besides a swelling polymer. CONSTITUTION: A sustained release formulation using a gastric retention drug delivery system comprises: a pharmacological activity component a swelling polymer a first controlled-release b...